medigraphic.com
Instituto Nacional de Salud Pública

2003, Number S3

<< Back Next >>

salud publica mex 2003; 45 (S3)

Prospects for controlling cervical cancer at the turn of the century

Franco EL, Duarte-Franco E, Ferenczy A

Language: English
References: 44
Page: 367-375
PDF size: 103.69 Kb.


ABSTRACT

Cervical cancer morbidity and mortality have decreased substantially during the last 50 years mostly due to successful organized or opportunistic screening with Pap cytology in high and middle income countries. In many low income countries Pap cytology screening is yet to be effectively implemented or has failed to reduce cervical cancer rates to an appreciable extent. The fact that infection with certain human papillomavirus (HPV) types is now recognized as a necessary cause of this disease has led to new research fronts on prevention of cervical cancer. Testing for HPV DNA has shown great promise as a screening tool with better sensitivity but somewhat lower specificity than Pap cytology. In combination with the latter, HPV testing has the potential to improve the negative predictive value of cytology, thus allowing for increased testing intervals, which would lower program costs with acceptable safety. Advances in cytology processing and automation have also led to new screening approaches that are increasingly gaining acceptance in high and middle income countries. For low income countries, visual inspection with acetic acid has proven to be an effective alternative to conventional Pap cytology, especially in settings where no screening programs have been implemented. Concerning primary prevention of cervical cancer, recent research on the safety and efficacy of candidate prophylactic vaccines against HPV have shown very promising results with nearly 100% efficacy in preventing persistent infections and development of cervical cancer precursors. However, policy makers are strongly cautioned to avoid deferring decisions concerning the implementation of cervical cancer screening under the expectation that a successful vaccine could obviate the need for secondary prevention strategies.


REFERENCES

  1. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann Intern Med 2000;132:810-819.

  2. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: Epidemiology, prevention, and role of human papillomavirus infection. Can Med Assoc J 2001;164:1017-1025.

  3. Koss LG. The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989;261:737-743.

  4. McGoogan E. Advantages and limitations of automated screening systems in developing and developed countries. In: Franco EL, Monsonego J, ed. New developments in cervical cancer screening and prevention. London: Blackwell, 1997:317-322.

  5. IARC Working Group. Human papillomaviruses. IARC Monographs on the evaluation of carcinogenic risks to humans. International Agency for Research on Cancer, Lyon: vol. 64, 1995;

  6. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L et al, ed. SEER Cancer Statistics Review, 1973-1997. Bethesda (MD) National Cancer Institute, 2000.

  7. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. Lyon: IARCPress, 2001; Version 1.0. IARC CancerBase No. 5.

  8. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841.

  9. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 18 major cancers in 1985. Int J Cancer 1993;54:594-606.

  10. Muir C, Waterhouse J, Mack T, Powell J, Whelan S. Cancer incidence in five continents. Lyon: International Agency for Research on Cancer, 1987;Vol. V. IARC Scientific Publications No. 88.

  11. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.

  12. Miller AB, Nazeer S, Fonn S, Brandup-Lukanow A, Rehman R, Cronje H, Sankaranarayanan R et al. Report on consensus conference on cervical cancer screening and management. Int J Cancer 2000;86:440-447.

  13. Gustafsson L, Sparen P, Gustafsson M, Wilander E, Bergstrom R, Adami HO. Efficiency of organised and opportunistic cytological screening for cancer in situ of the cervix. Br J Cancer 1995;72:498-505.

  14. Franco EL, Ferenczy A. Cervix. In: Franco EL, Rohan TE, ed. Cancer precursors: Epidemiology, detection, and prevention. New York: Springer-Verlag, 2002:249-286.

  15. Franco EL, Duarte-Franco E, Rohan TE. Evidence-based policy recommendations on cancer screening and prevention. Cancer Detect Prev 2002;26:350-361.

  16. Ferenczy A, Franco EL. Cervical-cancer screening beyond the year 2000. Lancet Oncol 2001;2:27-32.

  17. Ferenczy A, Robitaille J, Franco E, Arseneau J, Richart RM, Wright TC. Conventional cervical cytologic smears vs. thin prep smears. A paired comparison study on cervical cytology. Acta Cytol 1996;40:1136-1142.

  18. Hutchinson ML, Zahniser DJ, Sherman ME, Herrero R, Alfaro M, Bratti MC et al. Utility of liquid-based cytology for cervical carcinoma screening: Results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer 1999;87:48-55.

  19. Von Knebel-Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229-2242.

  20. Bibbo M, Klump WJ, DeCecco J, Kovatich AJ. Procedure for immunocytochemical detection of P16INK4A antigen in thin-layer, liquid-based specimens. Acta Cytol 2002;46:25-29.

  21. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ et al. American Cancer Society. Guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-362.

  22. Wilbur DC, Prey MU, Miller WM, Pawlick GF, Colgan TJ. The AutoPap system for primary screening in cervical cytology. Comparing the results of a prospective, intended-use study with routine manual practice. Acta Cytol 1998; 42: 214-220.

  23. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ. 2001;79:954-962.

  24. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox PM et al. Human papillomavirus testing in primary cervical screening. Lancet 1995;345:1533-1536.

  25. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I et al. HPV testing in primary screening of older women. Br J Cancer 1999;81:554-558.

  26. Schneider A, Hoyer H, Lotz B, Leistritza S, Kuhne-Heid R, Nindl I et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000;9:29-34.

  27. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M et al P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: A study of 7 932 women. Br J Cancer 2001; 84:1616-1623.

  28. Kuhn L, Denny L, Pollack A, Lörincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000;92:818-825.

  29. Wright TC Jr, Denny L, Kuhn L, Pollack A, Lörincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-86.

  30. Blumenthal PD, Gaffikin L, Chirenje ZM, McGrath J, Womack S, Shah K. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. Int J Gynaecol Obstet 2001;72:47-53.

  31. Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, Pan QJ et al. Shanxi Province cervical cancer screening study: A cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001;83:439-444.

  32. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S et al. HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.

  33. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000;9:945-951.

  34. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: Comparison of sensitivity, specificity, and frequency of referral. JAMA 2002; 288: 1749-1757.

  35. Cuzick J, for the HART Study Group. Baseline results for the HART multicentre HPV screening study of older women. 19th International Papillomavirus Conference; Florianópolis, September 1-7, 2001 Brazil (abstract # P-4).

  36. Solomon D. The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnoses. J Clin Cytol Cytopathol 1989;33:567-574.

  37. Franco EL, Ferenczy A. Assessing gains in diagnostic utility when human papillomavirus testing is used as a Pap smear adjunct for triaging women with cervical abnormalities. Am J Obstet Gynecol 1999;181: 382-386.

  38. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ et al. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999; 281:1605-1610.

  39. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-299.

  40. ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial. The atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS) Group. J Natl Cancer Inst 2000;92:397-402.

  41. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: Data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2002;94:102-107.

  42. Bosch FX, Lörincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55: 244-265.

  43. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93: 284-292.

  44. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-1651.




2020     |     www.medigraphic.com